Eguana Technologies could see revenue ramp, Mackie Research says

Eguana Technologies’ (Eguana Technologies Stock Quote, Chart TSXV:EGT) share price has been range-bound since mid-2018 but Mackie Research analyst Nikhil Thadani says that the stock could rapidly rerate as confidence builds for its quarterly revenue approaching and consistently exceeding the $2-$3 million mark.

Energy storage systems company Eguana announced its first quarter fiscal 2019 financials on March 1, reporting revenue of $850,000, with the company continuing to build its channel partners by adding more than 30 North American and Australian partnerships with distributors and solar dealers.

On Monday, the company announced a European exclusive agreement for its Enduro home storage system with Hanwha Q Cells, with Thadani saying that the deal will put EGT’s Enduro product immediately in front of more than 1,000 installers, including more than 600 installers in Germany alone.

“The company has laid some key foundations for scaling revenue in C2018,” says Thadani in a client update on Monday. “EGT improved order intake since last summer and has also been building out its installer and distribution partner network in the US, Europe and Australia, which bodes well for C2019 repeat orders. The next logical step in building the company’s platform should, therefore, relate to adding third party contract manufacturing in order to scale up capacity on the back of distribution partners’ initial orders, training and successful initial installations.”

Thadani says he’s optimistic that the Q Cells contract could provide about $3 million in revenue potential in the first year alone and more than $20 million over three years.

The analyst is maintaining his “Speculative Buy” rating and $0.70 target, representing a projected return of 233 per cent at the time of publication.

Tagged with: egt
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Elmet Group is a buy, this analyst says

Roth Capital Partners analyst Chip Moore says Elmet Group (The Elmet Group Stock Quote, Chart, News, Analysts, Financials NASDAQ:ELMT) remains… [Read More]

2 days ago

Rogers Communications: Buy, Sell or Hold?

Desjardins Securities analyst Jerome Dubreuil says Rogers Communications (Rogers Communications Stock Quote, Chart, News, Analysts, Financials TSX:RCI.B) could temporarily look… [Read More]

2 days ago

Meta is not an expensive stock, this fund manager says

Harris Douglas Asset Management partner and portfolio manager Paul Harris says Meta (Meta Stock Quote, Chart, News, Analysts, Financials NASDAQ:META)… [Read More]

2 days ago

MDA Space has “home run” potential, this analyst says

Beacon Securities analyst Russell Stanley says MDA Space’s (MDA Space Stock Quote, Chart, News, Analysts, Financials TSX:MDA) $688-million Canadian Space… [Read More]

3 days ago

The U.S. is not a risk for a recession, RBC says

RBC chief economist Frances Donald says the U.S. consumer has remained resilient, but persistent inflation has weakened household buffers and… [Read More]

3 days ago

Maritime Launch Services is a buy, this analyst says

Beacon Securities analyst Russell Stanley says Maritime Launch Services (Maritime Launch Services Stock Quote, Chart, News, Analysts, Financials TSXV:MAXQ) offers… [Read More]

3 days ago